## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.97 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (47% of avg), momentum weakening (-6.2% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($182.21)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. Feld Michael, EVP at Becton Dickinson, sells $14502 in stock**
- Source: Investing.com | 20251202T184400 | Neutral | Relevance: 99%
- Michael Feld, Executive Vice President at Becton Dickinson & Co (NYSE:BDX), sold 75 shares of common stock for a total of $14,502 on December 1, 2025, according to an SEC filing. Following the transaction, Feld directly owns 16,580 shares. This sale was part of a Rule 10b5-1 trading plan adopted in February 2025.

**2. Is Becton, Dickinson and Company Stock Underperforming the Nasdaq?**
- Source: Markets Financial Content | 20251201T092900 | Neutral | Relevance: 98%
- Becton, Dickinson and Company (BDX) has underperformed the Nasdaq Composite, with its stock slipping 23% from its 52-week high and showing weaker gains over three months, YTD, and the past 52 weeks. Despite this, the company's Q4 results exceeded EPS expectations, and analysts maintain a "Moderate Buy" rating with a potential upside. BDX's underperformance is attributed to macro challenges, including vaccine demand and biosciences research headwinds.

**3. BD Launches Portable PureWick Device to Help Women Manage Urinary Incontinence on the Go**
- Source: The Healthcare Technology Report. | 20251201T132120 | Bullish | Relevance: 98%
- BD has expanded its PureWickâ„¢ portfolio with a new portable urine collection system for individuals managing urinary incontinence, particularly wheelchair users, offering greater flexibility outside the home. The battery-powered device utilizes external suction technology in a lightweight, mobile form factor with up to eight hours of battery life. This innovation aims to enhance confidence and independence by providing a discreet, accessible solution for managing incontinence in daily activities and travel.

**4. Insider Sell: Michael Feld Sells Shares of Becton Dickinson & Co (BDX)**
- Source: GuruFocus | 20251202T200100 | Neutral | Relevance: 98%
- Michael Feld, Executive Vice President, Chief Revenue Officer & President of Life Sciences at Becton Dickinson & Co (BDX), sold 75 shares of the company on December 1, 2025. This transaction follows a total of 247 shares sold by Feld over the past year, with no purchases. The stock was trading at $193.36, indicating it is modestly undervalued according to GuruFocus's GF Value.

**5. FDA flags risk from dropped BD Alaris pumps after 2 injury reports**
- Source: MedTech Dive | 20251202T161812 | Neutral | Relevance: 97%
- The FDA has issued a Class I recall for BD Alaris pump modules after two reports of serious injuries stemming from dropped or severely jarred devices. BD has advised users to immediately remove such devices from use and have them tested by qualified personnel due to potential hidden damage that could lead to dangerous infusion errors. This follows previous issues and recalls for the Alaris pumps, though BD recently reported strong installations of its current pump models.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 13 ($0.04M) |
| Sells | 6 ($0.07M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.97 indicates undervaluation relative to growth. Balance sheet: $2.7B free cash flow. Analyst sentiment positive (1 raises, avg +7%). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.9B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.97 |
| Forward P/E | 12.0 |
| Current P/E | 12.8 |
| YoY Growth | 6.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.4% to -0.8% (-6.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.8pp (needs >4.0% for momentum thesis). Below SMA200 (0.99x), long-term trend not supportive. RSI neutral at 52. Volume at 47% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.81% (CS: 49) | Neutral |
| RSI_14 | 52.3 | Neutral |
| MACD Histogram | 0.23 | Bullish |
| vs SMA20 | 1.010x | Above |
| vs SMA50 | 1.016x | Above |
| vs SMA200 | 0.993x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $190.47
- **Stop Loss:** $182.21 (4.3% risk)
- **Target:** $206.99 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 121
- **Position Value:** $23,046.87
- **Portfolio %:** 23.05%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*